Hikma expands licensing agreement with Rovi for their enoxaparin biosimilar

Product, Press Release

Hikma expands licensing agreement with Rovi for their enoxaparin biosimilar

London, 24 April 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable), the multinational pharmaceutical group, announces that it has signed a licensing agreement with Laboratorios Farmaceúticos Rovi SA (ROVI:SM) for their enoxaparin biosimilar.

Rovi’s enoxaparin sodium is a biosimilar to Sanofi-Aventis’ Lovenox® and Clexane®, which is an anticoagulant medication that belongs to low molecular weight heparin class. It is used to treat and prevent deep vein thrombosis and pulmonary embolism. As of March 2018, Rovi had achieved national authorisation for their biosimilar of enoxaparin in 16 European markets.

Under the terms of the agreement, Hikma has the exclusive rights to distribute and market enoxaparin across its MENA markets.[1]

Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, “We are very pleased to be expanding our partnership with Rovi, adding this important cardiovascular product to our product portfolio in the MENA region. This partnership demonstrates the successful execution of our strategy to grow our biosimilar portfolio and improve patients' access to high-quality, affordable medicines.”

Juan López-Belmonte Encina, Rovi Chief Executive Officer said, “Rovi is very excited to announce our recent agreement with Hikma, a global pharmaceutical company, with a strong presence across the MENA region. By leveraging Hikma’s strong local presence, patients across the region will be able to access our enoxaparin biosimilar. In this new phase, together with Hikma, we aim to expand Rovi’s global footprint and become a leader in the low-molecular-weight heparin field.”

[1] The agreement does not include Morocco. In Lebanon, the agreement is only semi-exclusive.